Company · mentioned 5 times
Biopharmaceutical company, formerly based in San Diego, known for developing diabetes and obesity medicines including the GLP-1-related drug exenatide (Byetta) and pramlintide (Symlin); acquired by Bristol-Myers Squibb in 2012.
No connections recorded yet.
Invest Like the Best with Patrick O'Shaughnessy · 21 Apr